Palmer Square Capital BDC Inc. ("Palmer Square" or the "Company"), an externally managed business development company, today announced that it will release its financial results for the fourth quarter ...

Forrester Research, Inc. will broadcast its fourth-quarter and full-year earnings conference call at 4:30 p.m. ET on February 11, 2025. The call will be available at Forrester.com. Investors who wish ...

Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2024 financial results will be released ...

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $32.73 which represents a slight increase of $0.35 or 1.08% from the prior close of $32.38. The stock opened at $32.92 and touched a ...

Stephens reiterated their equal weight rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research report report ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.32 billion focused on developing and commercializing new medicines for difficult-to-treat cancers, has been ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from ...

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of ...

On Friday, Exelixis Inc (EXEL) stock saw a decline, ending the day at $32.38 which represents a decrease of $-1.75 or -5.13% from the prior close of $34.13. The stock opened at $33.49 and touched a ...

Fintel reports that on January 24, 2025, Oppenheimer downgraded their outlook for Exelixis (NasdaqGS:EXEL) from Outperform to ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...